title: [Effect of atypical antipsychotics on metabolism].
abstract: The metabolic effect of atypical antipsychotic drugs may manifest itself in weight gain, disturbances in glucose homeostasis and dyslipidemia. One confounding factor is that psychotic disorders themselves make the patients prone to specific metabolic changes. Nevertheless clinical studies have confirmed that atypical anti-psychotic drugs have a different metabolic effect. In the present prospective case-series, four male antipsychotic drug-naive psychiatric patients without any familial history of metabolic disorder were studied. The patients received risperidone or olanzapine monotherapy for 12 weeks; weight, plasma levels of triglyceride, cholesterol, HDL, and fasting glucose were measured in every 4th week. In two patients, oral glucose tolerance test (OGTT) was also performed at days 0 and 56. The average weight gain during the 12-week period was 12%. The cholesterol and triglyceride plasma concentrations were also elevated. The fasting glucose levels did not change during the observation period. In the OGTT performed in two patients, normal fasting glucose and insulin plasma levels were observed after 8 weeks; however, the plasma insulin concentrations were highly elevated after glucose intake, which may suggest the presence of insulin resistance. Our preliminary results confirmed the previous results on the metabolic effect of atypical anti-psychotic drugs, which may lead to metabolic syndrome. The regular control of the metabolic laboratory parameters, early intervention and the modification of the atypical antipsychotic treatment may help to avoid this adverse effect of the drugs.
authors.affiliation: Debreceni Orvos és Egészségtudományi Centrum, Pszichiátriai Tanszék.
authors.forename: Cinnia Dóra
authors.initials: CD
authors.lastname: Bakos
authors.forename: Roland
authors.initials: R
authors.lastname: Berecz
authors.forename: István
authors.initials: I
authors.lastname: Degrell
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000494:pharmacology*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D008076:Cholesterol, HDL / Q000097:blood* / Q000187:drug effects; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood*; D007333:Insulin Resistance; D008297:Male; D000077152:Olanzapine; D011446:Prospective Studies; D018967:Risperidone / Q000008:administration & dosage / Q000494:pharmacology*; D018490:Serotonin Agents / Q000494:pharmacology; D014280:Triglycerides / Q000097:blood*; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D008076:Cholesterol, HDL; D007328:Insulin; D018490:Serotonin Agents; D014280:Triglycerides; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine